Verastem Oncology
117 Kendrick Street
Suite 500
Needham
MA
02494
United States
Tel: (718) 292-4200
Website: http://www.verastem.com/
Email: info@verastem.com
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a clinical-stage biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer. We are driven by the strength, tenacity and courage of those battling cancer – single-minded in our resolve to deliver new therapies that not only keep cancer at bay, but improve the lives of patients diagnosed with cancer. Because for us, it’s personal.
Our team is anchored by core values of character, urgency, respect and excellence. We pride ourselves in being an organization committed to diversity and inclusion in order to achieve and sustain excellence. At Verastem, we believe that empowering employees is what makes them truly care about the important work they do.
Founded: 2010
425 articles about Verastem Oncology
-
Verastem, Inc. to Present at Upcoming Scientific and Investor Conferences
9/18/2013
-
Veristat, Inc. to Assist on Adaptive Enrichment Trial for Verastem, Inc.'s Defactinib in Mesothelioma
9/11/2013
-
Verastem, Inc. Initiates COMMAND: a Registration-Directed Trial of Defactinib in Patients With Mesothelioma
9/10/2013
-
Verastem, Inc. to Present at Upcoming Conferences
9/3/2013
-
Verastem, Inc. Issued U.S. Patent Covering VS-4718 Composition of Matter
8/15/2013
-
Verastem, Inc. Reports Second Quarter 2013 Financial and Corporate Results
8/13/2013
-
Verastem, Inc. to Present at 2013 Forbes Global CEO Conference
8/6/2013
-
Verastem, Inc. Receives Orphan Drug Designation from the U.S. FDA for Defactinib in Mesothelioma
7/24/2013
-
Verastem, Inc. Release: Defactinib in Combination With Weekly Paclitaxel Achieves a Complete Response in Platinum-Resistant Ovarian Cancer
7/23/2013
-
Verastem, Inc. Announces Closing of Public Offering and Exercise of Option to Purchase Additional Shares
7/23/2013
-
Verastem, Inc. Announces Pricing of Public Offering of Common Stock
7/22/2013
-
Verastem, Inc. Presents Results and Updated Development Plans at Annual Research and Development Day
7/12/2013
-
Verastem, Inc. to Present at the 8th Annual JMP Securities Healthcare Conference
7/2/2013
-
Verastem, Inc. Initiates Phase 1 Clinical Trial of VS-4718 in Patients With Advanced Cancer
6/26/2013
-
Verastem, Inc. Announces Annual Research and Development Day and Webcast
6/25/2013
-
Verastem, Inc. Receives Orphan Drug Designation in the EU for VS-6063 in Mesothelioma
6/13/2013
-
Verastem, Inc. Names Robert Forrester CEO
6/6/2013
-
Verastem, Inc. Hosts Dr. Dean Fennell for a Mesothelioma Briefing at American Society of Clinical Oncology
6/3/2013
-
Verastem, Inc. to Present at the 2013 American Society of Clinical Oncology Annual Meeting
5/23/2013
-
Verastem, Inc. to Present at Upcoming Conferences
5/21/2013